SCYNEXIS, Inc.
Long

SCYNEXIS Announces Positive Results from Interim Analyses of Ong

134
SCYX: Scynexis
2021-03-02 07:30:00
SCYNEXIS Announces Positive Results from Interim Analyses of Ongoing Phase 3 Studies (FURI and CARES), Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.